

**ASX ANNOUNCEMENT****4 October 2022****Scope of GMP manufacturing licence for  
Mildura facility extended**

**4 October 2022** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that the GMP manufacturing licence for the Company's flagship Mildura facility, which was issued by the Therapeutic Goods Administration (**TGA**) on 30 June 2022, has been extended to cover additional manufacturing capabilities.

The GMP manufacturing licence extension allows Cann Group to manufacture and release finished dried flower products for patient use at Mildura, and crops currently under cultivation at Mildura have been allocated to this purpose. The Company will utilise its GMP-approved laboratory testing capabilities to test patient-ready flower products released from the Mildura facility.

This licence extension is in addition to capabilities previously announced on 30 June 2022 covering the manufacture of dried flower as an Active Pharmaceutical Ingredient (**API**) and hard capsule manufacturing.

Cultivation, manufacturing, testing, and packaging are also being offered as a service to commercial clients.

Cann Group's CEO, Mr Peter Crock, said "This licence extension allows Cann to now manufacture patient-ready dried flower products at our Mildura facility, allowing us to quickly respond to market demands."

**Authorised for release by the Board of Directors of Cann Group Limited.**

**For all media enquiries please contact:**

Rhys Cohen  
Senior Corporate Communications Manager  
+61 449 679 095  
[rhys.cohen@canngrouponlimited.com](mailto:rhys.cohen@canngrouponlimited.com)

**For all other information please contact:**

Peter Crock  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)